权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer

探索结直肠癌新治疗空间的化学遗传学方法

基本信息

批准号：
10600844
负责人：
Ross Leigh Cagan
金额：
$ 13.86万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-01 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10600844
关键词：
Animals Apoptosis BRAF gene Benchmarking Biological Assay Biology Cancer Etiology Cancer Model Cells Cessation of life Chemical Modifier Chemicals Chemistry Clinical Colorectal Cancer Complex Computer Models Data Development Diagnosis Disease Drosophila genus Drug Design Drug Kinetics Epidermal Growth Factor Receptor Excretory function FDA approved Genes Genetic Genetic Screening Goals Half-Life Human Immunotherapy In Vitro KRAS2 gene Lead Libraries Malignant Neoplasms Maps Mediating Metabolism Modeling Modification Monomeric GTP-Binding Proteins Mus Nature Neoplasm Metastasis Oncogenic Patients Pharmaceutical Preparations Pharmacotherapy Phosphotransferases Primary carcinoma of the liver cells Property Protein Isoforms RAF1 gene Refractory Series Signal Transduction Structure Structure-Activity Relationship Survival Rate TP53 gene Testing Therapeutic Therapeutic Index Time Toxic effect Treatment Efficacy United States Variant Xenograft Model Xenograft procedure absorption analog aurora kinase A chemical genetics colon cancer cell line colon cancer patients comparative cost design drug development fly gastrointestinal genetic analysis genetic approach improved in vivo inhibitor innovation insight interdisciplinary approach kinase inhibitor metastatic colorectal mortality mutant neoplastic cell network attack novel novel therapeutic intervention novel therapeutics patient derived xenograft model side effect small molecule structural biology tumor tumor growth tumor initiation

项目摘要

Project Summary Metastatic colorectal cancer (mCRC) is the second leading cause of cancer-related mortality in the United States, and annually accounts for nearly 500,000 deaths worldwide. Currently, the small molecule kinase inhibitor (KI) regorafenib is the primary second line therapy for metastatic CRC that is not treatable with immunotherapy or anti-EGFR therapies. However, regorafenib generally provides only modest improvements in survival— typically months—and often at the cost of significant side effects. Proposed targets for regorafenib include kinases that act within tumor cells as well as non-autonomously; however, with over 500 possible targets in the human kinome, the exact mechanism by which this compound operates remains controversial and not fully known. This presents a daunting challenge; without a verifiable target or mechanism, no clear path exists to guide the development of improved therapies for mCRC. Here, we propose an alternative approach to drug development that focuses on kinase networks in the context of the whole animal. Specifically, we will take a multidisciplinary approach to define kinases that are beneficial to inhibit (‘pro-targets’) or avoid (‘anti-targets’) in the context of KRAS-variant CRC. Using Drosophila and mammalian models, we will identify kinases that—when reduced—alter the efficacy of regorafenib and similar compounds. We will also conduct extensive structure-activity relationship analyses, evaluating how modifications in already identified lead compounds impact changes in efficacy and therapeutic index. Finally, we will use computational structural biology to convert our chemical genetic insights into highly optimized and precise polypharmacological leads. In this final step, we generate new analogs to selectively eliminate putative anti-target activity while maintaining or increasing inhibitory activity against other beneficial targets. We have used our chemical genetic platform to identify a promising lead compound, APS5-86-2, that demonstrates significant activity relative to regorafenib in several mCRC models, including human patient derived xenografts (PDX). Comparative analysis suggests that the improved activity of APS5-86-2 relative to regorafenib derives from distinct polypharmacology on several RTKs and critical cancer drivers, including CDK9, AURKA, EGFR, BRAF, and RAF1. In this proposal, we examine the mechanism and importance of these and other putative pro- and anti-target kinases using genetic analysis and in vivo target engagement. The objective is to identify the kinase networks that mediate KRAS-variant mCRC by combining chemical biology with genetics, and to then derive inhibitors that best attack these networks through structure-based drug design. We have been successful previously with a similar approach, but in less complex tumor models (Dar et al., Nature, 2012; Sonoshita et al., Nature Chem. Bio., 2018); here we seek to extend our platform to a more prevalent disease with the goal of directly impacting mCRC by creating new, highly differentiated, and improved drugs.

项目总结